Trial Profile
Efficacy and Safety of EGT0001442 Compared With Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled by Diet and Exercise and up to One Oral Anti-diabetes Agent
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Bexagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Theracos
- 28 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Dec 2011 Actual initiation date changed from Jun 2011 to Dec 2011 as reported by ClinicalTrials.gov.
- 19 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.